GlobeNewswire All Public CompaniesQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:02:26·⚡ 决策 09-01 19:15:40 +13m14s·56.3 天前
Parabilis Medicines宣布CEO将于9月16日参加摩根士丹利第24届全球医疗健康大会炉边对话
这是标准的投资者关系会议出席通知，不含任何新增实质信息（无临床数据、无监管进展、无合作、无财务指引），对股价无催化作用，不构成可交易事件
📄 原文GlobeNewswire All Public Companies↗ 原文
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceut…
不做 Parabilis Medicines（PBLS.US）
例行会议出席通知，不含任何新增实质信息（无临床数据、无监管进展、无合作、无财务指引），不构成可交易催化剂
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Parabilis Medicines发布GlobeNewswire通稿，宣布CEO将于9月16日参加摩根士丹利全球医疗健康大会炉边对话。这是上市公司最常见的IR例行公告，不含任何新的临床数据、监管里程碑、商业合作或财务信息。会议本身在15天后，即使届时可能有新信息，当前公告本身不构成交易催化。结论：无事件、无edge、不做。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无——事件本身不构成催化，无需先例校准
方向:不适用——会议出席通知无历史价格反应可参考
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 718 ms
{"result": "search_processed_events:agent query=`parabilis fireside chat september 2026 | parabilis medicines conference participation | pbls morgan stanley global healthcare conference`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 61.7/72 小时、2082 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继
原文全文
展开原文 · 2,090 字
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24
th
Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.
The live audio webcast will be available on the Investors section of the Parabilis website at
investors.parabilismed.com
.
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric AR
ON
in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit
www.parabilismed.com
or follow us on
LinkedIn
.
Media Contact:
Jessica Freifeld
media@parabilismed.com
Investor Contact:
Tom Kotarakos
investors@parabilismed.com
th
Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.
The live audio webcast will be available on the Investors section of the Parabilis website at
investors.parabilismed.com
.
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric AR
ON
in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit
www.parabilismed.com
or follow us on
.
Media Contact:
Jessica Freifeld
media@parabilismed.com
Investor Contact:
Tom Kotarakos
investors@parabilismed.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。